Equities research analysts forecast that Beigene Ltd (NASDAQ:BGNE) will report earnings per share (EPS) of ($0.97) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Beigene’s earnings. The lowest EPS estimate is ($1.08) and the highest is ($0.86). Beigene also posted earnings per share of ($0.97) during the same quarter last year. The company is scheduled to announce its next earnings report on Wednesday, May 10th.
On average, analysts expect that Beigene will report full-year earnings of ($3.98) per share for the current fiscal year, with EPS estimates ranging from ($4.36) to ($3.60). For the next financial year, analysts forecast that the company will report earnings of ($4.01) per share, with EPS estimates ranging from ($4.33) to ($3.70). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Beigene.
Beigene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, March 22nd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.19. The business had revenue of $1 million for the quarter, compared to the consensus estimate of $3.75 million. During the same period last year, the business earned ($3.05) EPS. Beigene’s revenue for the quarter was down 78.6% on a year-over-year basis.
A number of research analysts recently commented on the stock. Maxim Group set a $52.00 price target on shares of Beigene and gave the company a “buy” rating in a research note on Thursday, March 2nd. Zacks Investment Research lowered shares of Beigene from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th.
In related news, CEO John Oyler sold 64,963 shares of the company’s stock in a transaction dated Tuesday, February 21st. The shares were sold at an average price of $40.55, for a total value of $2,634,249.65. Following the transaction, the chief executive officer now owns 378,383 shares in the company, valued at approximately $15,343,430.65. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Xiaodong Wang sold 14,461 shares of the company’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $40.80, for a total transaction of $590,008.80. Following the completion of the transaction, the director now owns 65,030 shares in the company, valued at approximately $2,653,224. The disclosure for this sale can be found here. In the last quarter, insiders sold 381,561 shares of company stock worth $15,180,155.
A number of hedge funds have recently bought and sold shares of BGNE. Baker BROS. Advisors LP acquired a new stake in Beigene during the third quarter worth about $58,930,000. Orbimed Advisors LLC acquired a new stake in Beigene during the fourth quarter worth about $27,436,000. Hillhouse Capital Management Ltd. acquired a new stake in Beigene during the third quarter worth about $21,567,000. FMR LLC increased its stake in Beigene by 18.1% in the fourth quarter. FMR LLC now owns 3,880,425 shares of the company’s stock worth $117,810,000 after buying an additional 593,896 shares in the last quarter. Finally, Boxer Capital LLC increased its stake in Beigene by 72.2% in the fourth quarter. Boxer Capital LLC now owns 850,000 shares of the company’s stock worth $25,806,000 after buying an additional 356,370 shares in the last quarter. 33.01% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/05/20/beigene-ltd-bgne-expected-to-announce-earnings-of-0-97-per-share-updated.html.
Shares of Beigene (NASDAQ:BGNE) opened at 37.44 on Wednesday. The company’s market capitalization is $1.34 billion. The firm’s 50-day moving average is $38.04 and its 200-day moving average is $34.94. Beigene has a 12-month low of $24.53 and a 12-month high of $42.09.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.